The Association Between Use of Inhaled Corticosteroids and Long‐Acting Beta2‐Agonists During Pregnancy and Adverse Fetal Outcomes
Respirology · 2026
DOI: 10.1111/resp.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respirology, 2026. Verfasst von Yea-Chwen Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Asthma, Adrenergic beta-2 Receptor Agonists, Adrenal Cortex Hormones, Pregnancy Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Science and Technology Council.
Abstract (Originalsprache)
Background and Objective Women with asthma should continue controller therapy during pregnancy, but current evidence on the effects of inhaled corticosteroids (ICS) and long‐acting beta2‐agonists (LABA) on adverse fetal outcomes remains unclear.
Methods
This was a population‐based retrospective cohort study. Data were derived from the Health and Welfare Database, Birth Certificate Application, and Maternal and Child Health Database in Taiwan, from January 1, 2007 to December 31, 2018. Pregnant women with asthma were enrolled. Three independent variables included ICS use, ICS dose–response effects, and LABA use during pregnancy. Adverse fetal outcomes included low birth weight, small for gestational age, preterm birth, and congenital anomalies. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to adjust for confounders, including sociodemographics, comorbidities, comedications, and asthma severity. Logistic regression models were used to calculate adjusted odds ratios (aORs).
Results
There were 4538 pregnant women with asthma enrolled in this study. After adjustment, neither ICS nor LABA use was significantly associated with any adverse fetal outcomes. However, among women exposed to ICS, high‐dose ICS use during pregnancy was associated with a significantly higher risk of congenital anomalies (aOR: 3.87; 95% CI: 1.29–11.60) within 1 year of delivery.
Conclusions
ICS or LABA use during pregnancy was not associated with the risk of adverse fetal outcomes. Pregnant women with asthma should be advised to maintain controller therapy and avoid potential allergens to reduce the need for high‐dose ICS. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan.
- Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Department of Pharmacy, College of Pharmaceutical Sciences, National Yang, Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Yea-Chwen Wu, Chung-Hsuen Wu
Förderung
- Ministry of Science and Technology, Taiwan
- National Science and Technology Council
Zitieren
APA
Wu, Y. C., Wang, I. T., Huang, H. Y., & Wu, C. H. (2026). The Association Between Use of Inhaled Corticosteroids and Long‐Acting Beta2‐Agonists During Pregnancy and Adverse Fetal Outcomes. Respirology. https://doi.org/10.1111/resp.70124
Vancouver
Wu YC, Wang IT, Huang HY, Wu CH. The Association Between Use of Inhaled Corticosteroids and Long‐Acting Beta2‐Agonists During Pregnancy and Adverse Fetal Outcomes. Respirology. 2026. doi:10.1111/resp.70124
BibTeX
@article{Wu2026,
author = {Wu, Yea-Chwen and Wang, I-Te and Huang, Hsin-Yi and Wu, Chung-Hsuen},
title = {The Association Between Use of Inhaled Corticosteroids and Long‐Acting Beta2‐Agonists During Pregnancy and Adverse Fetal Outcomes},
journal = {Respirology},
year = {2026},
doi = {10.1111/resp.70124}
}
EUVIMED